IL258913B - Plasminogen replacement therapy for plasminogen-deficiency - Google Patents

Plasminogen replacement therapy for plasminogen-deficiency

Info

Publication number
IL258913B
IL258913B IL258913A IL25891318A IL258913B IL 258913 B IL258913 B IL 258913B IL 258913 A IL258913 A IL 258913A IL 25891318 A IL25891318 A IL 25891318A IL 258913 B IL258913 B IL 258913B
Authority
IL
Israel
Prior art keywords
plasminogen
treatment
replacement
deficiency
plasminogen deficiency
Prior art date
Application number
IL258913A
Other languages
English (en)
Hebrew (he)
Other versions
IL258913A (en
Original Assignee
Prometic Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biotherapeutics Inc filed Critical Prometic Biotherapeutics Inc
Publication of IL258913A publication Critical patent/IL258913A/en
Publication of IL258913B publication Critical patent/IL258913B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL258913A 2015-11-03 2018-04-24 Plasminogen replacement therapy for plasminogen-deficiency IL258913B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562250235P 2015-11-03 2015-11-03
PCT/IB2016/001599 WO2017077380A1 (en) 2015-11-03 2016-11-03 Plasminogen replacement therapy for plasminogen-deficiency

Publications (2)

Publication Number Publication Date
IL258913A IL258913A (en) 2018-06-28
IL258913B true IL258913B (en) 2021-12-01

Family

ID=58661917

Family Applications (1)

Application Number Title Priority Date Filing Date
IL258913A IL258913B (en) 2015-11-03 2018-04-24 Plasminogen replacement therapy for plasminogen-deficiency

Country Status (24)

Country Link
US (1) US11291711B2 (https=)
EP (1) EP3370760B1 (https=)
JP (1) JP6878423B2 (https=)
KR (1) KR102821400B1 (https=)
CN (1) CN108289935A (https=)
AU (1) AU2016347863B2 (https=)
BR (1) BR112018008965A8 (https=)
CA (1) CA3002915C (https=)
DK (1) DK3370760T3 (https=)
ES (1) ES3055824T3 (https=)
FI (1) FI3370760T3 (https=)
IL (1) IL258913B (https=)
LT (1) LT3370760T (https=)
MX (1) MX2018005588A (https=)
MY (1) MY199581A (https=)
PL (1) PL3370760T3 (https=)
PT (1) PT3370760T (https=)
RS (1) RS67519B1 (https=)
RU (1) RU2736831C2 (https=)
SI (1) SI3370760T1 (https=)
SM (1) SMT202500451T1 (https=)
TW (1) TWI801331B (https=)
WO (1) WO2017077380A1 (https=)
ZA (1) ZA201802820B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201722464A (zh) * 2015-11-10 2017-07-01 波麥堤克生化科學有限公司 用於傷口癒合之纖維蛋白溶酶原給藥方案
CA3008185C (en) * 2015-12-18 2024-01-16 Talengen International Limited Method for prevention or treatment of acute and chronic thrombosis
WO2017101867A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防或治疗糖尿病性神经损伤及其相关病症的方法
TWI624268B (zh) * 2015-12-18 2018-05-21 Talengen Institute Of Life Sciences Co Ltd 纖溶酶原在製備藥劑上的用途及包括纖溶酶原之藥劑
TWI725092B (zh) 2015-12-18 2021-04-21 大陸商深圳瑞健生命科學硏究院有限公司 纖溶酶原在製備預防或治療糖尿病腎病或其相關病症之藥劑上的用途
WO2017161354A1 (en) * 2016-03-17 2017-09-21 Vanderbilt University Enhancing plasmin activity to prevent soft tissue calcification
WO2018107707A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种改善心脏病变的方法
JP7175270B2 (ja) * 2016-12-15 2022-11-18 タレンゲン インターナショナル リミテッド グルカゴン、インスリンを正常なバランスに戻らせる方法
US11207387B2 (en) 2016-12-15 2021-12-28 Talengen International Limited Method and drug for preventing and treating obesity
US11154595B2 (en) * 2016-12-15 2021-10-26 Talengen International Limited Method for preventing and treating pulmonary fibrosis
WO2018107688A1 (zh) * 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗脂肪肝的方法
CA3067890A1 (en) * 2017-06-19 2018-12-27 Talengen International Limited Method for regulating and controling glp-1/glp-1r and drug
CN109125715A (zh) * 2017-06-19 2019-01-04 深圳瑞健生命科学研究院有限公司 一种调控glp-1/glp-1r的方法和药物
TWI868051B (zh) * 2017-06-23 2025-01-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
CN113597313A (zh) 2019-01-24 2021-11-02 先觉药业咨询公司 用于治疗和预防微血栓形成的纤溶酶原
EP3812772B1 (en) * 2019-10-24 2025-02-19 Hôpitaux Universitaires de Strasbourg (HUS) Method for diagnosing fibrinolytic insufficiency related to neutrophil extracellular traps
US12497607B2 (en) 2020-04-23 2025-12-16 Previpharma Consulting Gmbh Plasminogen for use in treating and preventing lung dysfunction
CN114354929A (zh) * 2022-01-07 2022-04-15 南京鼓楼医院 一种用于监测人体纤溶状态的试剂盒及应用
WO2025049724A1 (en) * 2023-08-29 2025-03-06 Board Of Regents Of The University Of Nebraska Compositions and methods for treating pleural space infections and hemothorax

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115551A (en) * 1973-12-18 1978-09-19 Choay S.A. Compounds of the plasminogen type and method for obtaining such compounds from placental pulps
WO1994001128A1 (en) * 1992-07-01 1994-01-20 Beth Israel Hospital Boston Enhancement of thrombolytic therapy with deglycosylated plasminogen
US5304383A (en) * 1990-10-11 1994-04-19 Immuno Aktiengesellschaft Pharmaceutical preparation based on Lys-plasminogen
US20080090751A1 (en) * 2001-09-06 2008-04-17 Omnio Healer Ab Method of promoting healing of a tympanic membrane perforation
US20100028321A1 (en) * 2006-08-28 2010-02-04 Omnio Healer Ab Drug target for preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2764264B2 (ja) * 1987-10-01 1998-06-11 株式会社ミドリ十字 線溶活性増強剤
EP0682700A4 (en) * 1993-02-05 1997-05-28 Vascular Lab USE OF UROKINASE-LIKE PLASMINOGEN ACTIVATORS IN THE INTERIOR OF PLATES FOR THE LONG-TERM INHIBITION OF THROMBOSE.
US20030224516A1 (en) * 2002-06-03 2003-12-04 Isis Pharmaceuticals Inc. Antisense modulation of prox-1 expression
US20050271636A1 (en) * 2002-08-09 2005-12-08 St. Jude Children's Research Hospital, Inc. Diagnostic and therapeutic uses for prox 1
GB0509438D0 (en) * 2005-05-09 2005-06-15 Prometic Biosciences Ltd Affinity adsorbets for fibrinogen
AU2007290881B2 (en) * 2006-08-28 2013-03-07 Omnio Healer Ab Candidates against infection
WO2011004011A1 (en) * 2009-07-10 2011-01-13 Thrombogenics Nv Variants of plasminogen and plasmin
CN103221070B (zh) * 2010-08-30 2019-07-12 哈佛大学校长及研究员协会 用于狭窄病变和溶解血栓疗法的切变控制释放
PY1577621A (es) * 2014-12-19 2017-10-02 Prometic Biotherapeutics Inc Composicion farmaceutica que comprende plasminogeno y uso para el mismo
WO2017101870A1 (zh) * 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防或治疗糖尿病性视网膜病变的方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115551A (en) * 1973-12-18 1978-09-19 Choay S.A. Compounds of the plasminogen type and method for obtaining such compounds from placental pulps
US5304383A (en) * 1990-10-11 1994-04-19 Immuno Aktiengesellschaft Pharmaceutical preparation based on Lys-plasminogen
WO1994001128A1 (en) * 1992-07-01 1994-01-20 Beth Israel Hospital Boston Enhancement of thrombolytic therapy with deglycosylated plasminogen
US20080090751A1 (en) * 2001-09-06 2008-04-17 Omnio Healer Ab Method of promoting healing of a tympanic membrane perforation
US20100028321A1 (en) * 2006-08-28 2010-02-04 Omnio Healer Ab Drug target for preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HEIDEMANN ET AL.,, TREATMENT OF LIGNEOUS CONJUNCTIVITIS WITH TOPICAL PLASMIN AND TOPICAL PLASMINOGEN''., 31 December 2003 (2003-12-31) *
KRAFT ET AL.,, LIGNEOUS CONJUNCTIVITIS IN A GIRL WITH SEVERE TYPE I PLASMINOGEN DEFICIENCY''., 31 December 2000 (2000-12-31) *
PATRICK WATTS ET AL,, EFFECTIVE TREATMENT OF LIGNEOUS CONJUNCTIVITIS WITH TOPICAL PLASMINOGEN, 1 April 2002 (2002-04-01) *
SCHOTT ET AL.,, THERAPY WITH A PURIFIED PLASMINOGEN CONCENTRATE IN AN INFANT WITH LIGNEOUS CONJUNCTIVITIS AND HOMOZYGOUS PLASMINOGEN DEFICIENCY., 31 December 1998 (1998-12-31) *

Also Published As

Publication number Publication date
EP3370760A4 (en) 2019-06-26
DK3370760T3 (da) 2025-12-22
ES3055824T3 (en) 2026-02-16
WO2017077380A1 (en) 2017-05-11
KR102821400B1 (ko) 2025-06-18
PT3370760T (pt) 2025-12-03
SI3370760T1 (sl) 2026-02-27
RU2736831C2 (ru) 2020-11-20
SMT202500451T1 (it) 2026-01-12
IL258913A (en) 2018-06-28
BR112018008965A8 (pt) 2019-02-26
US11291711B2 (en) 2022-04-05
MY199581A (en) 2023-11-07
CA3002915C (en) 2024-01-16
TWI801331B (zh) 2023-05-11
CA3002915A1 (en) 2017-05-11
ZA201802820B (en) 2019-07-31
EP3370760B1 (en) 2025-10-01
NZ742657A (en) 2024-04-26
PL3370760T3 (pl) 2026-03-23
JP2018533589A (ja) 2018-11-15
TW201722463A (zh) 2017-07-01
AU2016347863A1 (en) 2018-06-07
AU2016347863B2 (en) 2023-11-09
RS67519B1 (sr) 2025-12-31
LT3370760T (lt) 2025-12-29
BR112018008965A2 (pt) 2018-11-21
RU2018120182A3 (https=) 2020-04-27
JP6878423B2 (ja) 2021-05-26
KR20180083348A (ko) 2018-07-20
US20190231854A1 (en) 2019-08-01
FI3370760T3 (fi) 2025-12-05
MX2018005588A (es) 2018-11-09
EP3370760A1 (en) 2018-09-12
CN108289935A (zh) 2018-07-17
RU2018120182A (ru) 2019-12-04

Similar Documents

Publication Publication Date Title
IL258913B (en) Plasminogen replacement therapy for plasminogen-deficiency
HRP20181692T1 (hr) Liječenje fibroze
LT3386323T (lt) Asmeninis garinimo prietaisas
HUE056287T2 (hu) Pancreatitis kezelése
PL3265053T3 (pl) Sposoby leczenia skóry
EP3344400A4 (en) Three dimensional microtissue bioprinter
EP3319446A4 (en) Healthful supplements
PL3212174T3 (pl) Sposoby leczenia zakażeń wirusem filoviridae
DK3851537T5 (da) Behandling af hyperbilirubinæmi
DK3395354T3 (da) Plasminogen til anvendelse i behandling af diabetisk nefropati
EP3334429C0 (en) HYPERPHENYLALANINEMIA AND TREATMENTS THEREFOR
PL3277270T3 (pl) Kompozycje i sposoby leczenia niedokrwistości
DK3231444T3 (da) Ny behandling
HUE050944T2 (hu) Kezelési eljárás tradipitant alkalmazásával
EP3360010A4 (en) BI PHOTONS WITH VOTABLE SOURCE
BR112018000204A2 (pt) métodos de tratamento de colite
DK3391902T5 (da) Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati
PL3393468T3 (pl) Metody leczenia niedoboru odporności
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
DK3307267T3 (da) Behandling af multipel sklerose
PL3238827T3 (pl) Młynek do kości
IL257764B (en) Methods for treatment of diseases
SI3188599T1 (sl) Zdravljenje na osnovi anamorelina
IL254825A0 (en) Methods of treatment with taselisib
IL256111B1 (en) Pac–1 combination therapy